These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10344921)

  • 1. Modelling different approaches to the management of upper gastrointestinal disease.
    Duggan AK
    Pharmacoeconomics; 1998; 14 Suppl 2():25-37. PubMed ID: 10344921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus guidelines for evaluating and treating patients with upper gastrointestinal symptoms in the primary care setting.
    Whitaker MJ
    Pharmacoeconomics; 1998; 14 Suppl 2():5-10. PubMed ID: 10344923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings.
    Haycox A; Butterworth M; Walley T; Barton S
    Pharmacoeconomics; 1998; 14 Suppl 2():11-23. PubMed ID: 10344920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease.
    Haycox A; Dubois D; Butterworth M
    Pharmacoeconomics; 1998; 14 Suppl 2():39-56. PubMed ID: 10344922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care.
    Duggan AE; Elliott CA; Miller P; Hawkey CJ; Logan RF
    Aliment Pharmacol Ther; 2009 Jan; 29(1):55-68. PubMed ID: 18801056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is upper gastrointestinal radiography a cost-effective alternative to a Helicobacter pylori "test and treat" strategy for patients with suspected peptic ulcer disease?
    Rich M; Scheiman JM; Tierney W; Fendrick AM
    Am J Gastroenterol; 2000 Mar; 95(3):651-8. PubMed ID: 10710053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
    Craig AM; Davey P; Malek M; Murray F
    Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost-effectiveness using decision analysis.
    Fendrick AM; Chernew ME; Hirth RA; Bloom BS
    Yale J Biol Med; 1996; 69(2):187-95. PubMed ID: 9112750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of routine endoscopic biopsies for Helicobacter pylori detection in patients with non-ulcer dyspepsia.
    Makris N; Crott R; Fallone CA; Bardou M; Barkun A
    Gastrointest Endosc; 2003 Jul; 58(1):14-22. PubMed ID: 12838214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
    Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
    Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of the restriction in the use piroxicam in Spain.
    Maciá Martínez MÁ
    Reumatol Clin; 2015; 11(6):345-52. PubMed ID: 25636384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
    Maetzel A; Ferraz MB; Bombardier C
    Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of dyspepsia in general practice. A critical assessment.
    Tosetti C; Stanghellini V
    Pharmacoeconomics; 1998; 14 Suppl 2():57-66. PubMed ID: 10344924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversy and consensus in the management of upper gastrointestinal disease in primary care. The International Gastro Primary Care Group.
    Whitaker MJ; Brun J; Carelli F
    Int J Clin Pract; 1997 Jun; 51(4):239-43. PubMed ID: 9287266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the dyspeptic patient: a cost-utility study.
    Ebell MH; Warbasse L; Brenner C
    J Fam Pract; 1997 Jun; 44(6):545-55. PubMed ID: 9191627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial.
    Mason JM; Raghunath AS; Hungin AP; Jackson W
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1297-303. PubMed ID: 18793340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Related to Upper Gastrointestinal Symptom Generation in 2275 Helicobacter pylori Seroprevalent Adults.
    Lee SP; Lee SY; Kim JH; Sung IK; Park HS; Shim CS
    Dig Dis Sci; 2017 Jun; 62(6):1561-1570. PubMed ID: 28281170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The health economics of Helicobacter pylori infection.
    Moayyedi P
    Best Pract Res Clin Gastroenterol; 2007; 21(2):347-61. PubMed ID: 17382282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical economics review: gastrointestinal disease in primary care.
    Jones RH
    Aliment Pharmacol Ther; 1996 Jun; 10(3):233-9. PubMed ID: 8791945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.